NCT02127437View on ClinicalTrials.gov

Lanreotide In Polycystic Kidney Disease Study

PHASE3CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

September 19, 2014

Primary Completion Date

July 31, 2019

Study Completion Date

July 31, 2019

Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Interventions
DRUG

Lanreotide

120 mg, subcutaneously, once every 4 weeks

DRUG

saline

0,5 ml, subcutaneously, once every 4 weeks

Trial Locations (1)

75015

Necker hospital, Paris

All Listed Sponsors
collaborator

IPSEN pharmaceutical company, Boulogne-Billancourt, France

UNKNOWN

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02127437 - Lanreotide In Polycystic Kidney Disease Study | Biotech Hunter | Biotech Hunter